Search

Palifermin

Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]

Laquinimod

It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.

Zenarestat

gamma-Tocopherol

gamma-Tocopherol is under investigation in clinical trial NCT00836368 (In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics).

Zinc dibutyldithiocarbamate

Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.

Ipragliflozin

Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

NP-50301

The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

Linsitinib

An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. … IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.

JSM 6427

It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.

Butylphthalide

Butylphthalide has been used in trials studying the prevention of Restenosis.